Publication at Faculty of Medicine in Pilsen |
2012
Abstract
Resistance to antiplatelets represents important limitation of secondary prevention of cardiovascular diseases. Residual platelet reactivity despite standard dual antiplatelet treatment is rather frequent condition and is associated by the excessive increase of coronary event, also with potentially fatal outcome.
The use of new antiplatelet drugs, such as prasugrel and ticagrelor seems to be better solution, than increase of dosage of standard antiplatelets.